What is Controversial about Hypertension Management? JNC 8 Guidelines: key new aspects What is new and what is controversial?

Similar documents
JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates. January 30, 2014

Supplementary Online Content

Special Communication

Treatment of Hypertension: JNC 8 and More

ADULT HYPERTENSION PROTOCOL STANFORD COORDINATED CARE

Hypertension and Diabetes

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk

9/19/2013. Standardizing Preventive Care for Hypertension. About the Speaker. About the Speaker

Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8)

DRUG UTILIZATION EVALUATION OF ANTIHYPERTENSIVE DRUGS IN DIABETIC PATIENTS WITH CKD

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY

Antihypertensive Drug Management to Achieve Systolic Blood Pressure <120 mmhg in SPRINT

From Concept to Rapid Visualization a Data Analytics Case Study

MIND-BODY THERAPIES FOR HYPERTENSION

MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES

Carefully review the risks and potential, but unproven, benefits of treatment.

HYPERTENSION: Comparison of New Guidelines

Obesity in the United States Workforce. Findings from the National Health and Nutrition Examination Surveys (NHANES) III and

Diabetic Nephropathy

Correspondence to: Rima B Shah (rima_1223@yahoo.co.in) DOI: /ijmsph Received Date: Accepted Date:

Submitted Electronically to

Aggressive Lowering of Blood Pressure in type 2 Diabetes Mellitus: The Diastolic Cost

High Blood Pressure (Essential Hypertension)

Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

Using multiple biomarkers to predict renal and cardiovascular drug efficacy: Implications for drug development and registration

Drug Treatment in Type 2 Diabetes with Hypertension

Case Study 6: Management of Hypertension

Absolute cardiovascular disease risk assessment

Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines

HYPERTENSION ASSOCIATED WITH RENAL DISEASES

Cardiovascular Risk in Diabetes

New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine

EXPANDING THE EVIDENCE BASE IN OUTCOMES RESEARCH: USING LINKED ELECTRONIC MEDICAL RECORDS (EMR) AND CLAIMS DATA

Cardiovascular Disease in Diabetes

Ruchika D. Husa, MD, MS Assistant t Professor of Medicine in the Division of Cardiology The Ohio State University Wexner Medical Center

DIET AND EXERCISE STRATEGIES FOR WEIGHT LOSS AND WEIGHT MAINTENANCE

Measure #236 (NQF 0018): Controlling High Blood Pressure National Quality Strategy Domain: Effective Clinical Care

OEM MAXNIBP Frequently Asked Questions

High Blood Pressure and Your Kidneys

FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES

Hypertension Guideline V4

Combination Antihypertensive Therapy: When to use it Diabetes

HIGH BLOOD PRESSURE AND YOUR KIDNEYS

Hypertension and Diabetes Status Bangladesh Demographic and Health Survey

PROMISE & PITFALLS OF OUTCOMES RESEARCH USING EMR DATABASES. Richard L. Tannen, M.D., Mark Weiner, Dawei Xie

Guidelines for the management of hypertension in patients with diabetes mellitus

How to measure blood pressure using digital monitors

Hypertension Guidelines

Getting the most from blood pressure medicines

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery

FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION NEW ENGLAND JOURNAL OF MEDICINE 2011; DOI: 10.

Renovascular Hypertension

Use of antihypertensive medications in patients with diabetes in Ajman, UAE

Blood Pressure Assessment Program Screening Guidelines

Approaches to the Management of Difficult-to-Control Hypertension

Population Differences Case Examples: Lessons from Past Trials

Vascular Risk Reduction: Addressing Vascular Risk

High Blood Pressure. What Is Blood Pressure?

Epidemiology of Hypertension 陈 奕 希 李 禾 园 王 卓

Marcus Wilson, PharmD. First Plenary Session

Understanding Diseases and Treatments with Canadian Real-world Evidence

High Blood Pressure and Kidney Disease

Hypertension Best Practices Symposium

The Cross-Sectional Study:

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

Treatment Issues of Diabetes, Hypertension, and Lipids in the Elderly Patient

Main Effect of Screening for Coronary Artery Disease Using CT

SUMMARY OF CHANGES TO QOF 2015/16 - ENGLAND CLINICAL

Cohort Studies. Sukon Kanchanaraksa, PhD Johns Hopkins University

U.S. Food and Drug Administration

Hypertension and Heart Failure Medications. Dr William Dooley

About High Blood Pressure

Pharmacy and the Medicaid Accountable Care Organization

Blood Pressure. Blood Pressure (mm Hg) pressure exerted by blood against arterial walls. Blood Pressure. Blood Pressure

Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007

Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.

HALT-PKD Trials

Mortality Assessment Technology: A New Tool for Life Insurance Underwriting

Corporate Medical Policy

Rx Updates New Guidelines, New Medications What You Need to Know

Prevention and management of chronic kidney disease in type 2 diabetes

GFR (Glomerular Filtration Rate) A Key to Understanding How Well Your Kidneys Are Working

ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL)

Current Renal Replacement Therapy in Korea - Insan Memorial Dialysis Registry, ESRD Registry Committee, Korean Society of Nephrology*

GUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY*

Chronic Kidney Disease (CKD) Algorithm. Chronic Kidney Disease (CKD) Algorithm Page 1

Type 2 Diabetes workshop notes

Advanced Clinical Decision Support & Acute Kidney Injury

RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra

Absolute cardiovascular disease risk management

Draft comprehensive global monitoring framework and targets for the prevention and control of noncommunicable diseases

Barostimulaatio ja renaalinen denervaatio

Insulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks

Research Skills for Non-Researchers: Using Electronic Health Data and Other Existing Data Resources

Blood Pressure Lowering in Type 2 Diabetes A Systematic Review and Meta-analysis

Transcription:

What is Controversial about Hypertension Management? JNC 8 Guidelines: key new aspects What is new and what is controversial?

Financial Disclosures Gabriel B. Habib, MD In the context of my participation in this CME activity: There is no conflict of interest to disclose.

What is new about Hypertension Management? Key Objectives 1. Importance of BP as a major CV risk factor 2. JNC 8 Goal BP based on age > or < 60 3. JNC 8 Goal BP for DM or CKD patients 4. JNC 8 Type of Rx for DM or CKD patients 5. JNC 8 Type of Rx for blacks FOCUS ON WHAT IS NEW AND WHAT IS CONTROVERSIAL COMPARED TO JNC 7 and common sense

BP>115 TC>150 Systematic Assessment of changes in population Health resulting from modification of 26 risk factors

115/75 115/75 61 cohort studies in 1 M Subjects 12.7 M-Y

3 simple questions JNC 8 addressed When? To start Rx THRESHOLD BP Where? To aim Rx GOAL BP How? To achieve that goal RX TYPE

JNC 8 Guidelines Evidence Quality Rating

JNC 7 2003 Guidelines BP Goal < 140 systolic and < 90 diastolic < 130 systolic and < 80 diastolic in diabetics and renal disease < 120/80 is optimal BP; 115/75 is associated with the lowest risk of CV and renal complications (observational studies) JNC 7 Flashback 2003..

The new and improved JNC 8 Target BP JNC 8 2014 Guidelines BP Goal SO what is really NEW about these guidelines?

The new and improved JNC 8 Target BP JNC 8 2014 Guidelines BP Goal SO what is really NEW about these guidelines?

JNC 8 took 10 years to conceive in Dec 2013 10 years after JNC 7 Was this wait really worth it? Is JNC 8 really a step forward? Or more like 3 steps backward?

The Media reacted to JNC 8 If true experts cannot decide or agree on a GOAL BP, maybe Journalists should decide! Time Magazine on January 14, 2014 Heart Disease Why Doctors Are Fighting Over Blood Pressure Guidelines? By Alexandria Sifferlin @acsifferlin Jan. 13, 2014 Alexandra Sifferlin is a writer and producer for TIME Healthland. She is a graduate from the Northwestern University Medill School of Journalism

Reactions to JNC 8 guidelines In an interview with the Associated Press, the American Heart Association s (AHA) president-elect Dr. Elliott Antman, a cardiologist at Brigham and Women s Hospital and a professor at Harvard Medical School in Boston, told the Associated Press the AHA was uneasy with the decision. We are concerned that relaxing the recommendations may expose more persons to the problem of inadequately controlled blood pressure, he said.

Some even lost their mind over the JNC 8 guidelines! Dr. Suzanne Steinbaum, the director of women and heart disease at Lenox Hill Hospital in New York said she has not changed the way she treats her patients over age 60. I have been waiting. I have been waiting for this editorial, she says. As a preventive cardiologist, these new guidelines have made me insane! What we have learned is that blood pressure treatment even for a patient above 80 has been shown to be critical. It goes against everything we know as cardiologists.

How are decisions reached in JNC 8? By majority vote Or Unanimously?

How are decisions reached in JNC 8? By majority vote Or Unanimously?

So what would the minority do after JNC 8 is reported? A. Keep quiet and simply yield to the majority. After all, that is how decisions are made in any civil society. We sometimes respectfully disagree but eventually come around to accept the majority vote OR B. Go out of their way to voice their discontent

So what would the minority do after JNC 8 is reported? A. Keep quiet and simply yield to the majority. After all, that is how decisions are made in any civil society. We sometimes respectfully disagree but eventually come around to accept the majority vote OR B. Go out of their way to voice their discontent

Minority View regarding Systolic BP goal change from < 140 to < 150 in subjects > 60 years old We, the panel minority, believed that evidence was insufficient to increase the SBP goal from its current level of less than 140 mm Hg because of concern that increasing the goal may cause harm by increasing the risk for CVD and partially undoing the remarkable progress in reducing cardiovascular mortality in Americans older than 60 years. In addition, one target would simplify implementation for clinicians. Jackson T. Wright Jr., MD, PhD Annals of Internal Medicine April 2014

SO why did JNC 8 change the GOAL BP to 150/90 in subjects 60 years and older? NO compelling evidence a GOAL < 140/90 is SUPPORTED BY randomized controlled clinical trials in subjects 60 years of age and older

Why less stringent BP goals in JNC 8? The recommendation by the JNC 8 to use a less stringent goal was based on two clinical trials conducted in Japan, which failed to show that lowering systolic BP below 140 mmhg improved cardiovascular outcomes compared with a higher target goal in elderly hypertensive patients. So what are these new studies telling us?

JATOS Japanese Clinical Trial DOES < 140 mm Hg GOAL SBP REDUCE CV complications MORE than GOAL SBP 140-160 mmhg in 65-85 year old hypertensive patients? ANSWER IS NO!! Study drug was efonidipine, a long-acting calcium antagonist similar to amlodipine. Final BP were significantly lower (136/75 vs. 146/78; p<0.001), but the primary endpoint was similar in the two groups (86 patients in each group; p=0.99).

Valsartan in Elderly Isolated Systolic Hypertension Study VALISH Trial In older subjects, is < 140 SBP more effective in reducing CV events compared to 150-159 mm Hg in a larger group of 3,260 older subjects? At 3 years, BP reached was 5.4/1.7 mm Hg lower No difference in the primary end point : 10.6/1000 vs. 12/1000 patient-years. Hazard ratio: 0.89; 95% CI: 0.60 to 1.34; P 0.38.

Editorial VALISH Hypertension 2010 The lower the better Paradigm has VANISHed NO RCT support for < 140 mm Hg SBP goal in older patients The SBP target of 140 mm Hg in the elderly, although recommended by JNC 7 2003 guidelines, remains unsupported.

Which would you believe? VALISH AND JATOS Trials or Observational studies? Should RCT evidence from 2 under powered trials in Japan weigh more than observational data even if the observational data are based on >50 studies over several decades and RCT evidence is limited to 2 RCT with important limitations?

Let us compare these weights! >50 observational studies vs 2 underpowered randomized trials

Let us compare these weights! For the JNC 8 Majority >50 Observational Studies 1 million patients worldwide 2 underpowered studies 7,678 patients In Japan 2 under powered clinical trials tip the scale and GOAL SBP SHOULD BE < 150 for subjects 60 y or older

Let us compare these weights! For the JNC 8 Minority 2 underpowered studies 7,678 patients In Japan >50 Observational Studies 1 million patients worldwide >50 observational studies tip the scale and GOAL SBP SHOULD BE < 140 for subjects 60 y or older

So, what are the answers to: 3 simple questions JNC 8 addressed? When? To start Rx THRESHOLD BP Where? To aim Rx GOAL BP How? To achieve that goal RX TYPE

So, what are the answers to: 3 simple questions JNC 8 addressed? When? To start Rx THRESHOLD BP Where? To aim Rx GOAL BP How? To achieve that goal RX TYPE

JNC 8 Recommendation 1 > 60 y BP < 150/90 Recommendation 1 Subjects aged > 60 y, initiate therapy at BP > 150/90 and treat to goal BP < 150/90 mm Hg Strong Recommendation Grade A Corollary Recommendation If pharmacologic treatment results in lower achieved SBP <140 mm Hg and treatment is not associated with adverse effects on health or quality of life, treatment does not need to be adjusted. Expert Opinion Grade E

JNC 8 Recommendation 2 < 60 y DBP<90 Recommendation 2 Subjects < 60 y, initiate therapy at DBP of > 90 and treat to goal DBP < 90 mm Hg. For age 30-59 y: Strong Recommendation Grade A For ages 18 through 29 y, Expert Opinion Grade E

JNC 8 Recommendation 3 < 60y SBP <140 Recommendation 3 Subjects < 60 years, initiate therapy at SBP > 140 mm Hg and treat to goal SBP of < 140 mm Hg. Expert Opinion Grade E

JNC 8 Recommendation 4 CKD < 140/90 Recommendation 4 Subjects > 18 y with CKD, initiate therapy at BP > 140/90 and treat to goal BP < 140/90 mm Hg. Expert Opinion Grade E

WHY GOAL BP 140/90 in CKD? Evidence is insufficient to determine if there is a benefit in mortality, or CV outcomes with drug therapy to a lower BP goal <130/80 compared with <140/90 mm Hg. Evidence of moderate quality demonstrating no benefit in slowing the progression of kidney disease from treatment with therapy to BP goal <130/80 compared with a goal < 140/90 mm Hg

JNC 8 Recommendation 5 Diabetics <140/90 Recommendation 5 Subjects > 18 y with diabetes, initiate treatment at BP of > 140/90 & treat to goal BP < 140/90 mm Hg. Expert Opinion Grade E

WHY Goal BP < 140/90 in JNC 8 for Diabetics? No RCTs addressed whether treatment to goal SBP < 140 mm Hg compared with <150 mm Hg improves health outcomes in adults with diabetes and hypertension. In the absence of such evidence, panel recommends BP goal < 140/90 Hg in this population based on expert opinion SBP <140 IS NOT PROVEN TO LOWER CV OUTCOMES VS < 150

JNC 8 Goal BP < 140 vs <130 in Diabetics SBP goal of lower than 130 mm Hg is commonly recommended for adults with diabetes and hypertension. However, this lower SBP goal is not supported by any RCT ACCORD-BP compared SBP goal < 120 mm Hg with goal < 140 mm Hg. NO difference in the primary cardiovascular outcome

So, what are the answers to: 3 simple questions JNC 8 addressed? When? To start Rx THRESHOLD BP Where? To aim Rx GOAL BP How? To achieve that goal RX TYPE 140/90 except for those > 60 years: 150/90 mm Hg

So, what are the answers to: 3 simple questions JNC 8 addressed? When? To start Rx THRESHOLD BP Where? To aim Rx GOAL BP How? To achieve that goal RX TYPE

JNC 8 Recommendation 6 Non black + Diabetics Recommendation 6 Non Blacks including diabetics, initial treatment should include a thiazide-type diuretic, CCB, ACEI or ARB. Moderate Recommendation Grade B

JNC 8 Recommendation 7 Blacks + Diabetes Recommendation 7 Blacks including diabetics, initial treatment should include a thiazide-type diuretic or CCB. Blacks: Moderate Recommendation Grade B Blacks with diabetes: Weak Recommendation Grade C

JNC 8 Recommendation 8 CKD ACEI/ARB Recommendation 8 Subjects > 18 y with CKD and hypertension, initial (or add-on) antihypertensive treatment should include an ACEI or ARB to improve kidney outcomes. This applies to all CKD patients regardless of race or diabetes status. Moderate Recommendation Grade B

JNC Recommendation 9 Multiple Rx Recommendation 9 The main objective of hypertension treatment is to attain and maintain goal BP. If goal BP is not reached within a month, increase the dose of initial drug or add a second drug from one of the classes in recommendation 6 (thiazide-type diuretic, CCB, ACEI, or ARB). If goal BP cannot be reached with 2 drugs, add and titrate a third drug from this list. Do not use ACEI and ARB together in the same patient. Expert Opinion Grade E

3 simple questions JNC 8 addressed When? To start Rx THRESHOLD BP Where? To aim Rx GOAL BP How? To achieve that goal RX TYPE

So what are the answers to the 3 simple questions JNC 8 addressed? When? To start Rx THRESHOLD BP Where? To aim Rx GOAL BP 140/90 or 150/90 depending on age < or > 60 How? To achieve that goal RX TYPE Diuretic, ACEI, ARB or CCB -no preference- unless CKD (ACEI or ARB) or Black (diuretic or CCB)